pharmaceuticals

pharmaceuticals Articles

The April 13 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Eli Lilly released its most recent quarterly earnings report before the markets opened on Tuesday.
Creating a treatment for a rare disease or rare disorder can come with massive upside if the treatment is successful. That said, the risk is that a company can implode if its rare disease treatment...
24/7 Wall St. has put together a preview of AbbVie, Eli Lilly and some of the other top pharma and biotech companies reporting their latest quarterly results in the coming week.
Incyte and Eli Lilly will be under the microscope next week as the FDA will decide the fate of their rheumatoid arthritis treatment.
Ionis Pharmaceuticals shares made a handy gain on Friday after the firm announced an expanded strategic collaboration with Biogen.
GW Pharmaceuticals won an FDA approval for its cannabis-derived drug, but shares were relatively muted on Thursday.
Rigel Pharmaceuticals shares retreated early Wednesday despite an approval from the FDA for its treatment of thrombocytopenia.
GW Pharmaceuticals shares saw a solid gain on Tuesday after the FDA released some briefing documents pertaining to an upcoming approval meeting. Needless to say, investors are taking this as a...
Rheumatoid arthritis is an autoimmune disease that attacks tissues within the joints, and it is a major target of U.S. and foreign biotechnology and pharmaceutical companies.
Bellicum Pharmaceuticals shares pulled back on Tuesday after the firm announced that it would be conducting a secondary offering to raise some cash.
Johnson & Johnson (NYSE: JNJ) reported its first quarter financial results before the markets opened on Tuesday. The company said that it had $2.06 in earnings per share (EPS) on $20.01 billion...
Lung cancer may have just met a new standard of care. On top of that, it would be considered a new standard as a first line of care in lung cancer and longer overall survival rates.
Over the past week, a few biotech companies made absolutely massive runs, while others fell off a cliff. Although health care has barely kept pace with the broader markets over the past 52 weeks, the...
Bellicum Pharmaceuticals saw its shares rise early on Thursday after the firm announced a critical decision from the FDA.